We had the pleasure of meeting up with Prof. Michael Hill (University of Calgary, Calgary, Canada) to discuss the use of nerinetide in the treatment of patients who had an acute ischaemic stroke, and the findings from the ESCAPE-NA1 trial.
The session entitled “Nerinetide for LVO Neuroprotection: Fact or Fiction?” was presented at the 7th European Stroke Conference, 1-3 September 2021.
Questions:
- What is the rationale for the use of nerinetide in the treatment of patients who had an acute ischaemic stroke? (0:21)
- What were the aims and methodology of the ESCAPE-NA1 trial? (1:07)
- What were the findings of the study? (2:42)
- Did any subgroups respond well to nerinetide? (4:20)
- What will be the next steps in the clinical development of nerinetide in this indication? (5:47)
Disclosures: Michael Hill has provided consultant services to Boehringer-Ingelheim, Sun Pharma, Boston Scientific.
Support: Interview and filming supported by Touch Medical Media. Interview filmed by Katey Gabrysch.
Filmed in coverage of ESOC 2021.
